Evidence map›Paper›PMID 40666293›Full record

ArticleEJHaem2025

Post-Diagnosis Hemorrhagic Events Are Strongly Associated With Poor Survival in Patients With Essential Thrombocythemia.

Yoshinori Hashimoto, Tomoki Ito, Akihiko Gotoh, Mika Nakamae, Fumihiko Kimura, Michiaki Koike, Keita Kirito, Hideho Wada, Kensuke Usuki, Takayuki Tanaka and 15 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJHaem, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Yoshinori HashimotoDepartment of Hematology Tottori Prefectural Central Hospital Tottori Tottori Japan.ORCID https://orcid.org/0000-0002-3374-9814
Tomoki ItoFirst Department of Internal Medicine Kansai Medical University Hirakata Osaka Japan.
Akihiko GotohDepartment of Hematology Tokyo Medical University Shinjuku-ku Tokyo Japan.ORCID https://orcid.org/0000-0002-8608-4393
Mika NakamaeDepartment of Hematology Osaka Metropolitan University Graduate School of Medicine Osaka Japan.
Fumihiko KimuraDivision of Hematology National Defense Medical College Tokorozawa Saitama Japan.
Michiaki KoikeDepartment of Hematology Juntendo University Shizuoka Hospital Izunokuni Shizuoka Japan.
Keita KiritoDepartment of Hematology and Oncology University of Yamanashi Chuo-Shi Yamanashi Japan.
Hideho WadaDepartment of Hematology Kawasaki Medical School Kurashiki Okayama Japan.
Kensuke UsukiDepartment of Hematology NTT Medical Center Tokyo Shinagawa Tokyo Japan.
Takayuki TanakaDepartment of Hematology Tottori Prefectural Central Hospital Tottori Tottori Japan.
Takehiko MoriDivision of Hematology Keio University School of Medicine Shinjuku-ku Tokyo Japan.
Satoshi WakitaDepartment of Hematology Nippon Medical School Bunkyo City Tokyo Japan.
Toshiki I SaitoClinical Research Center NHO Nagoya Medical Center Nagoya Aichi Japan.
Akiko KadaClinical Research Center NHO Nagoya Medical Center Nagoya Aichi Japan.
Akiko M SaitoClinical Research Center NHO Nagoya Medical Center Nagoya Aichi Japan.ORCID https://orcid.org/0000-0003-3723-8445
Kazuya ShimodaDivision of Hematology Diabetes, and Endocrinology Department of Internal Medicine Faculty of Medicine University of Miyazaki Miyazaki Miyazaki Japan.
Yuka SugimotoDepartment of Hematology and Oncology Mie University Tsu Mie Japan.
Toshiro KurokawaDepartment of Hematology Toyama Red Cross Hospital Toyama Japan.
Akihiro TomitaDepartment of Hematology Fujita Health University School of Medicine Toyoake Aichi Japan.
Yoko EdahiroDepartment of Hematology Juntendo University School of Medicine Bunkyo City Tokyo Japan.
Hitoshi KiyoiDepartment of Hematology and Oncology Nagoya University Graduate School of Medicine Nagoya Aichi Japan.
Koichi AkashiDepartment of Medicine and Biosystemic Science Kyushu University Fukuoka Fukuoka Japan.
Itaru MatsumuraDepartment of Hematology and Rheumatology Faculty of Medicine Kindai University Higashiosaka Osaka Japan.
Katsuto TakenakaDepartment of Hematology Clinical Immunology and Infectious Diseases Ehime University Graduate School of Medicine Toon Ehime Japan.
Norio KomatsuDepartment of Hematology Juntendo University School of Medicine Bunkyo City Tokyo Japan.ORCID https://orcid.org/0000-0003-1880-9126

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: The present study investigated the effects of thrombosis, hemorrhagic events, disease progression, and secondary malignancies on patient survival after the diagnosis of essential thrombocythemia (ET). Methods: We analyzed data from 1152 patients enrolled in the JSH-MPN-18 study using time-dependent Cox regression and multistate Markov models to estimate transition hazards and state occupation probabilities. Results: Hemorrhagic events (hazard ratio = 2.92, 95% confidence interval = 1.78-4.78, Conclusions: The present results demonstrated that hemorrhagic events following the diagnosis of ET are a serious risk factor and are directly related to early death. Baseline characteristics and post-diagnosis events (intermediate status) may both have a significant impact on survival, and treatment strategies that take into account the prevention of an intermediate status need to be incorporated into clinical practice. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission.

Indexed as

essential thrombocythemiahemorrhagic eventmultistate Markov modelpoor prognosis

Identifiers

PMID40666293
PMCPMC12260263

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.